We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
-15.67%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.15B
AUM Growth
-$535M
Cap. Flow
+$215M
Cap. Flow %
6.83%
Top 10 Hldgs %
73.8%
Holding
31
New
2
Increased
19
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$57M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$46.9M
3
JUNO
Juno Therapeutics, Inc.
JUNO
+$37.5M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$36.5M
5
KITE
Kite Pharma, Inc.
KITE
+$25.2M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$126M
2
INVA icon
Innoviva
INVA
+$5.99M
3
TBPH icon
Theravance Biopharma
TBPH
+$4.68M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$2.42M
5
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$917K

Sector Composition

Rank Sector Weight
1 Healthcare 83.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.2B
$414M 13.12%
3,750,406
+10,000
+0.3% +$1.12M
CELG
2
DELISTED
Celgene Corp
CELG
$388M 12.31%
3,589,298
+25,000
+0.7% +$3.1M
RDUS
3
DELISTED
Radius Health, Inc.
RDUS
$296M 9.39%
4,272,140
+350,000
+9% +$24.3M
GILD icon
4
Gilead Sciences
GILD
$167B
$272M 8.64%
2,774,596
+59,000
+2% +$6.55M
IONS icon
5
Ionis Pharmaceuticals
IONS
$9.04B
$268M 8.5%
6,634,838
+705,412
+12% +$36.5M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$162M 5.13%
1,034,428
+257,000
+33% +$46.9M
AGIO icon
7
Agios Pharmaceuticals
AGIO
$2.08B
$149M 4.72%
2,109,921
+120,000
+6% +$11.7M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$124B
$142M 4.51%
1,365,445
+31,000
+2% +$3.98M
NBIX icon
9
Neurocrine Biosciences
NBIX
$18.2B
$126M 4%
3,171,552
-50,000
-2% -$2.42M
MDVN
10
DELISTED
MEDIVATION, INC.
MDVN
$110M 3.48%
2,581,112
– –
REGN icon
11
Regeneron Pharmaceuticals
REGN
$72.9B
$95.4M 3.02%
205,000
+7,000
+4% +$3.76M
HALO icon
12
Halozyme
HALO
$9.84B
$93.1M 2.95%
6,929,832
+852,664
+14% +$17.1M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$38.1B
$91M 2.89%
1,132,499
+167,000
+17% +$18.6M
NVAX icon
14
Novavax
NVAX
$1.2B
$58.9M 1.87%
416,500
+7,500
+2% +$1.68M
CLVS
15
DELISTED
Clovis Oncology, Inc.
CLVS
$56.8M 1.8%
618,188
– –
JUNO
16
DELISTED
Juno Therapeutics, Inc.
JUNO
$53.1M 1.68%
1,305,000
+855,000
+190% +$37.5M
CEMP
17
DELISTED
Cempra, Inc.
CEMP
$52.7M 1.67%
1,891,900
+125,000
+7% +$4.64M
ALDR
18
DELISTED
Alder Biopharmaceuticals
ALDR
$49.5M 1.57%
1,510,150
+355,000
+31% +$15.1M
TSRO
19
DELISTED
TESARO, Inc.
TSRO
$46.3M 1.47%
1,154,582
+250,000
+28% +$13.7M
KITE
20
DELISTED
Kite Pharma, Inc.
KITE
$41.8M 1.32%
750,000
+400,000
+114% +$25.2M
PBYI icon
21
Puma Biotechnology
PBYI
$397M
$39.3M 1.25%
521,991
– –
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$35M 1.11%
210,719
+30,000
+17% +$6.6M
PTCT icon
23
PTC Therapeutics
PTCT
$6.12B
$34.8M 1.1%
1,302,912
+50,000
+4% +$2.14M
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$22.8M 0.72%
2,700,737
– –
ESPR
25
DELISTED
Esperion Therapeutics
ESPR
$21.4M 0.68%
+908,542
New +$57M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q3 2015 Portfolio in Review

As of Q3 2015, BB Biotech held 31 positions worth $3.15B, down 15% from $3.69B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

BB Biotech deployed $215M of net new capital in Q3 2015, opening 2 new positions and adding to 19 existing holdings. Its largest new stake was Esperion Therapeutics: 908,542 shares worth $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 82% a quarter earlier.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $2.42M trimmed.

  • BB Biotech's largest Q3 2015 buy was Esperion Therapeutics: 908,542 shares worth $21.4M.
  • BB Biotech added most to Alexion Pharmaceuticals in Q3 2015, an estimated $46.9M increase.
  • BB Biotech's biggest Q3 2015 reduction was Neurocrine Biosciences, cutting an estimated $2.42M.
  • BB Biotech fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $126M.
  • BB Biotech's ten largest holdings make up 74% of its $3.15B portfolio in Q3 2015.
  • BB Biotech opened 2 new positions and closed 3 in Q3 2015.
  • BB Biotech's portfolio value fell 15% quarter-over-quarter to $3.15B.

Based on BB Biotech's 13F filing for Q3 2015, filed 12 Nov 2015.